Wake-up haul: an Ozempic moment for the brain

概览

This episode of The Intelligence looks at three separate questions: whether orexin agonists could become the next major drug class after GLP-1 medicines, why Japan produces so few globally significant startups, and what research says about procrastination.

The first discussion explains orexin as a brain neuropeptide involved in wakefulness, with new drugs aimed first at narcolepsy and potentially, much later, at conditions such as depression, ADHD and addiction. The comparison with Ozempic-style “everything drugs” is presented as promising but still early.

The second segment argues that Japan’s startup weakness comes from limited venture capital, low social status for entrepreneurs and a tendency for startups to list publicly too soon. The final segment treats procrastination as a measurable self-regulation problem linked to income, health and mental health, then reviews behavioral, exercise, diet and medication-related evidence.

分段落总结

[01:19] Episode Setup

[事实] The hosts introduce the show as The Intelligence from The Economist. [事实] The episode previews two later topics: Japan’s weak startup scene and ways to overcome procrastination. [事实] The first substantive segment focuses on peptides, GLP-1 drugs and the pharmaceutical search for the next big class of medicines.

[01:52] Orexin as the Next Drug Target

[事实] Shailesh Chitnis explains that orexin is a neuropeptide found in the brain. [事实] Orexin agonists are described as medicines that mimic orexin’s action. [事实] Orexin’s main role is regulating wakefulness and the boundary between sleep and waking. [推测] The “Ozempic moment” framing comes from the hope that orexin drugs could move beyond one initial condition into wider medical uses, as GLP-1 medicines did.

[03:02] Narcolepsy and New Orexin Drugs

[事实] A drug called ovoperextone, made by Takeda, is described as having been approved by the FDA to treat narcolepsy. [事实] Narcolepsy is described as a condition in which the boundary between sleep and wakefulness is blurred, sometimes causing people to fall asleep without warning. [事实] A severe form can involve cataplexy, where muscles freeze. [事实] Alkermes and Eli Lilly are also mentioned as companies working on orexin-agonist drugs; Lilly acquired Sentessa Pharmaceuticals in a deal worth almost $7.8 billion.

[04:21] How Orexin Was Discovered

[事实] In the late 1990s, independent researchers converged on orexin. [事实] Stanford researcher Emmanuel Mignot studied narcolepsy in dog breeds including Dobermans and Labradors. [事实] His work linked the condition to a genetic mutation that made the dogs fail to respond to orexin. [事实] Human trials later supported the finding that people with narcolepsy lack enough orexin molecules in the brain.

[05:28] Potential Uses Beyond Narcolepsy

[事实] Narcolepsy is described as rare, affecting roughly one in 1,000 to one in 2,000 people worldwide. [事实] Animal trials suggest orexin may also affect reward-seeking behavior, motivation and related brain functions. [事实] Drugmakers hope orexin agonists could eventually be useful for depression, ADHD and addictions. [推测] The discussion treats these broader uses as the source of the biggest commercial and medical excitement, but also the biggest uncertainty.

[06:41] Market Potential and GLP-1 Comparison

[事实] A Morgan Stanley report is cited estimating that orexin medicines could generate almost $16 billion a year by 2035. [事实] Current narcolepsy drugs are said to have annual sales of around $3 billion. [事实] GLP-1 medicines are compared because they began with diabetes, expanded into obesity and are now being studied or used for other conditions. [事实] Shailesh cautions that drug discovery has many promising ideas that never reach the market.

[10:10] Japan’s Startup Problem

[事实] The episode contrasts Japan’s postwar entrepreneurial successes, including Sony and Honda, with its current weak startup record. [事实] SoftBank is also cited as a company that began as a small software distributor run by a 24-year-old. [事实] Ethan Wu says only six of around 1,400 unicorns worldwide were born in Japan. [推测] The segment frames Japan’s startup weakness as a structural problem rather than a lack of historical entrepreneurial ability.

[11:43] Shortage of Venture Capital

[事实] Ethan identifies a shortage of risk-taking capital as the first major problem. [事实] Modern venture capital in Japan is described as relatively new, barely existing until the mid-2010s. [事实] VC fundraising has increased sharply in the past decade but remains small compared with peer markets. [事实] Japan has more early-stage capital than late-stage capital, making it harder for startups to scale.

[12:49] Low Cultural Status of Startups

[事实] Ethan says startups in Japan suffer from low cultural standing. [事实] A Global Entrepreneurship Monitor survey found that 24% of Japanese respondents consider entrepreneurship a desirable occupation, compared with a global average of 67%. [事实] Founders and startup employees are seen as taking risky or questionable career gambles. [推测] This cultural skepticism likely reduces both the supply of founders and the willingness of employees to leave established companies.

[13:33] Rushing to IPO

[事实] The third problem is that Japanese startups often go public too quickly. [事实] Japanese venture capitalists are described as pressuring startups to IPO quickly so investors can cash out. [事实] Japan has historically had too little M&A activity, limiting alternative exit routes. [事实] Japan’s IPOs are described as closer to a US Series B fundraising round than a major public-market debut.

[14:44] Why Early IPOs Hurt Growth

[事实] Critics say rushing to IPO distracts startups from long-term growth and global expansion. [事实] Japan’s public markets are described as having many small, stagnant listings. [事实] At the end of 2025, the median market capitalization of firms debuting on the Tokyo Stock Exchange’s growth market was 10 billion yen, or $61 million. [事实] Historically lax delisting rules and social credibility from being public reduced pressure on underperforming firms.

[15:55] Government and Exchange Reforms

[事实] Japan’s government introduced a comprehensive startup plan in 2022 to improve legitimacy and provide financial and logistical support. [事实] The Tokyo Stock Exchange has announced that from 2030, companies unable to maintain a 10 billion yen market cap after five years will be delisted. [事实] More than half of firms on the TSE growth market may not meet that bar. [事实] TSE chief executive Yamaji Hiromi says the aim is to make IPOs a starting point rather than the end goal.

[16:55] Signs of Startup Momentum

[事实] Japan’s number of homegrown unicorns has risen from one or two a decade ago to six. [事实] M&A activity, private equity activity and startup acquisitions have increased. [事实] AI is described as a tailwind, with Sakana AI named as Japan’s most valuable unicorn and a maker of large language models. [事实] Japan has not yet created a decacorn, unlike Australia and Korea, which are said to have five and six respectively.

[18:23] Procrastination as a Serious Problem

[事实] Rosie introduces procrastination through ordinary delayed tasks such as expenses, house cleaning and taking a parcel to the post office. [事实] Benjamin Sutherland says procrastination can reduce income and harm physical and mental health. [事实] Researchers refer to procrastination as self-regulatory failure. [推测] The segment treats procrastination less as a harmless habit and more as a behavioral pattern with measurable consequences.

[19:03] Evidence on Income and Health

[事实] A 2013 study of 23,000 Americans found that each one-point increase on a procrastination scale was associated with a $15,000 drop in annual earnings. [事实] A 2023 study found that frequent procrastinators also put off medical treatment and were more likely to suffer debilitating pain. [事实] An analysis of 88 studies with more than 63,000 participants in 17 countries found that procrastination reduced self-esteem and predicted future depression.

[20:08] Why Procrastination May Be Increasing

[事实] Benjamin says people appear to be procrastinating more than earlier generations. [事实] Working from home is cited as one reason, because the boss is not looking over workers’ shoulders. [事实] Smartphones are cited as a source of endless distraction. [事实] Smartphones can also delay bedtime, and less sleep is linked to more self-regulatory failure.

[20:47] Mental and Physical Interventions

[事实] One intervention is called mental contrasting with implementation intentions. [事实] It involves stating a goal, contrasting it with the obstacle and devising a tactic to overcome the obstacle. [事实] Randomized trials found that this approach can work, especially for bedtime procrastination. [事实] Physical exercise is described as an even more powerful way to counter procrastination.

[21:34] Exercise and Self-Mastery

[事实] A Chinese study assigned some of 77 teenage boys to exercise and found that they procrastinated less by the end of the trial. [事实] A 2022 Chinese trial found that physically active participants were less likely to procrastinate. [事实] Researchers suggested that overcoming uncomfortable physical exertion creates a sense of mastery, boosting confidence to tackle unpleasant tasks. [推测] Exercise may help procrastination partly by training tolerance for discomfort rather than simply improving mood.

[22:23] Diet, Habits and Causality

[事实] Researchers have looked for links between diet, food and procrastination. [事实] A 2024 Italian study of university students found that skipping breakfast, heavy smoking and heavy drinking were associated with more procrastination. [事实] Researchers hypothesized that skipping breakfast may reduce the blood sugar boost needed for focus. [事实] The study could not determine which factor caused the other.

[23:10] Medication and Executive Function

[事实] Benjamin says there are currently no medications that target procrastination. [事实] A 2021 American study of adults with ADHD tested the stimulant lisdexamfetamine. [事实] Participants who received the stimulant showed large gains in cognitive executive function, including task initiation, compared with those given a placebo. [事实] Benjamin says the result is promising but follow-up studies are still needed.

播客点评/总结

This episode is valuable because it moves quickly across business, science and behavior while keeping each topic anchored in concrete studies, companies and market figures. The orexin discussion is especially strong in showing why pharmaceutical excitement can be both rational and premature.

The Japan segment gives a clear structural explanation for a familiar puzzle: why a country with famous postwar corporate successes has produced relatively few modern unicorns. Its strongest point is the connection between capital markets, cultural attitudes and premature IPOs.

The procrastination segment is practical without becoming a self-help list. It distinguishes evidence-backed interventions from weaker associations, especially when discussing diet and medication.

[推测] The episode is best suited to listeners who want concise, evidence-led briefings on business and science rather than a deep technical treatment of any single topic. Its limitation is that each subject is compressed, so several claims are introduced with little room for methodological detail.